Replies to post #123110 on Biotech Values

[genisi]

I'm sure data will also be analyzed by AD severity at start, as treating mild patients is expected to be more efficient than treating more advanced ones. Question is do they have enough mild patients in the trial to see a stat-sig effect in this group.